Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M211,085Revenue $M49,605Net Margin (%)18.7Altman Z-Score2.8
Enterprise Value $M219,613EPS $1.4Operating Margin %25.9Piotroski F-Score6
P/E(ttm)23.6Beneish M-Score-2.7Pre-tax Margin (%)25.4Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %2.6Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %4.4Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow17.2y-y EBITDA Growth Rate %-9.8ROA % (ttm)5.4Higher Current Ratio y-yY
Dividend Yield %3.2PEG5.3ROE % (ttm)12.4Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M6,158ROIC % (ttm)12.1Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEKahn Brothers 2015-03-31 Reduce-0.39%$31.16 - $35.05
($33.51)
$ 34.282%Reduce 3.83%1,811,016
PFEJames Barrow 2015-03-31 Reduce-0.32%$31.16 - $35.05
($33.51)
$ 34.282%Reduce 12.24%55,080,222
PFENWQ Managers 2015-03-31 Reduce-0.16%$31.16 - $35.05
($33.51)
$ 34.282%Reduce 6.64%5,927,532
PFEJoel Greenblatt 2015-03-31 Add0.15%$31.16 - $35.05
($33.51)
$ 34.282%Add 38.84%1,972,788
PFECharles Brandes 2015-03-31 Reduce-0.07%$31.16 - $35.05
($33.51)
$ 34.282%Reduce 2.37%6,123,536
PFEDavid Dreman 2015-03-31 Add0.03%$31.16 - $35.05
($33.51)
$ 34.282%Add 70.38%25,202
PFEMario Gabelli 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 34.282%Reduce 5.80%896,431
PFEDodge & Cox 2015-03-31 Reduce-0.01%$31.16 - $35.05
($33.51)
$ 34.282%Reduce 0.89%46,776,959
PFERichard Pzena 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 34.282%Reduce 0.50%2,159,618
PFEFirst Eagle Investment 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 34.282%Reduce 0.12%5,266,820
PFEJohn Keeley 2015-03-31 Reduce$31.16 - $35.05
($33.51)
$ 34.282%Reduce 1.27%98,689
PFEKen Fisher 2015-03-31 Add$31.16 - $35.05
($33.51)
$ 34.282%Add 0.04%31,208,271
PFEKahn Brothers 2014-12-31 Reduce-0.49%$27.7 - $32.09
($30.23)
$ 34.2813%Reduce 5.14%1,883,217
PFEFirst Eagle Investment 2014-12-31 Add0.39%$27.7 - $32.09
($30.23)
$ 34.2813%Add 3786.85%5,272,943
PFERichard Pzena 2014-12-31 Buy 0.36%$27.7 - $32.09
($30.23)
$ 34.2813%New holding2,170,568
PFEVanguard Health Care Fund 2014-12-31 Add0.32%$27.7 - $32.09
($30.23)
$ 34.2813%Add 29.88%19,395,622
PFEMichael Price 2014-12-31 Sold Out -0.17%$27.7 - $32.09
($30.26)
$ 34.2813%Sold Out0
PFEKahn Brothers 2014-09-30 Reduce-0.59%$28.04 - $30.96
($29.58)
$ 34.2816%Reduce 6.56%1,985,161
PFEMichael Price 2014-09-30 Reduce-0.22%$28.04 - $30.96
($29.58)
$ 34.2816%Reduce 56.02%47,100
PFEFirst Eagle Investment 2014-09-30 Reduce-0.16%$28.04 - $30.96
($29.58)
$ 34.2816%Reduce 94.11%135,661
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SUSMAN SALLYExecutive Vice President 2015-03-12Sell46,179$340.82view
READ IAN CChairman & CEO 2015-03-05Sell67,500$34.62-0.98view
Dolsten MikaelPresident R&D 2015-03-05Sell58,298$34.46-0.52view
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-02-13Sell104,000$34.73-1.3view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-12Sell9,000$34.85-1.64view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell80,200$34.230.15view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell14,800$34.3-0.06view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-10Sell9,000$33.781.48view
MADDALUNA ANTHONY JExecutive Vice President 2014-12-08Sell6,500$327.13view
HILL CHARLES HExecutive Vice President 2014-11-10Sell8,285$30.1813.59view

Press Releases about PFE :

    Quarterly/Annual Reports about PFE:

      News about PFE:

      Articles On GuruFocus.com
      Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer May 22 2015 
      Joel Greenblatt Increases Position in Pfizer May 17 2015 
      Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
      Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
      Endo International Posts Upbeat Q1 Results May 13 2015 
      Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
      Pfizer is a Good Buy Post Recent Results May 03 2015 
      Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
      Crouching Tigers, Hidden Assets – Smead Capital Management Apr 30 2015 
      Currency Woes Impact Pfizer Sales In Q1, Management Lowers Future Guidance Apr 29 2015 

      More From Other Websites
      Germany's Merck expects drug division to drive growth-Euro am Sonntag May 23 2015
      Germany's Merck expects drug division to drive growth-Euro am Sonntag May 23 2015
      Would Pfizer Buying GlaxoSmithKline Make Sense? May 22 2015
      Esperion Therapeutics: 15 Reasons to Take Profits May 22 2015
      Could M&A Boost Pfizer More? Jefferies Thinks So May 22 2015
      Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy May 22 2015
      In a quiet stock market, whispers of an M&A wave May 22 2015
      Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
      All Eyes on Pfizer as Shareholders Await the Mega-Deal May 22 2015
      All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A May 21 2015
      How a "PfizerKline" would impact the Triangle May 21 2015
      3 Big Pharmaceutical Stocks to Buy Right Now May 21 2015
      Takeover talk sends FTSE higher May 20 2015
      Hedge Funds Love These 5 Big Stocks -- but Should You? May 20 2015
      How biotechs are affecting J&J's business May 20 2015
      Pfizer To See Boosting Revenues On New Drugs Growth Through 2020 May 20 2015
      Pfizer Would Benefit From Glaxo Takeover, Deutsche Bank Says May 20 2015
      Who are Pfizer's (PFE) main competitors? May 20 2015
      JNJ's 'balance approach' accounts for success: CEO May 20 2015
      [$$] Merck Could Struggle to Hit Health Care Heights May 19 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      SEENSCO
      ReplySEENSCO - 11 months ago
      PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK